ArticleTherapeutic advances in medical oncology2025

Real-world analysis of HER2-ultralow in HR+/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomes.

Laurent Mathiot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.